Schlossmacher Lab

Michael Schlossmacher profile picture

Contact Information

Michael Schlossmacher, MD, DABPN, FRCPC
613-562-5462

Administrative Assistant:
Nancy MacDonald
nmacdonald@toh.ca
613-562-5462

For those interested in a position in the laboratory, please contact:
Dr. Julianna Tomlinson
jtomlins@uottawa.ca

Publications

Selected Publications

Shutinoski B, et al. Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner. Sci Transl Med. 2019 Sep 25;11(511). pii: eaas9292. doi: 10.1126/scitranslmed.aas9292.

Tomlinson JJ et al. Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. J Neural Transm 2017; 124(6): 721-738

Schlossmacher MG et al. Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults : the PREDIGT score. Eur J Neuroci. 2017; 45(1) :175-191

Cullen V* et al. Acid beta-glucosidase mutations linked to Gaucher disease, Parkinson's and Lewy body dementia dysregulate alpha-synuclein in vivo. Ann Neurol 2011;69:940-53 
*This paper was awarded the editor's ‘Annals of Neurology Prize' in 2012 

Hakimi M et al. Parkinson's-linked LRRK2 is expressed in immune cells and upregulated after the recognition of microbial structures. J Neural Transm 2011;118:795-808  

Mollenhauer B* et al. Cerebrospinal fluid values of alpha-synuclein and tau in patients presenting with parkinsonism. Lancet Neurol 2011;10:230-40 and Lancet Neurol 2011;10:681-3;
*See also the opinion piece published in: Lancet Neurol 2011;10(3):203-5

All Other Publications

Shutinoski B, Patel R, Tomlinson JJ, Schlossmacher MG, Sad S. Ripk3 licenced protection against microbial infection in the absence of Caspase1-11 inflammasome. Microbes Infect. 2019 Aug 17. pii: S1286-4579(19)30085-1. doi: 10.1016/j.micinf.2019.08.002. 

Xu H, Boucher FR, Nguyen TT, Taylor GP, Tomlinson JJ, Ortega RA, Simons B, Schlossmacher MG, Saunders-Pullman R, Shaw W, Bennett SAL. DMS as an orthogonal separation to LC/ESI/MS/MS for quantifying isomeric cerebrosides in plasma and cerebrospinal fluid. J Lipid Res. 2019 Jan;60(1):200-211. doi: 10.1194/jlr.D089797. Epub 2018 Nov 9.

Shutinoski B, Alturki NA, Rijal D, Bertin J, Gough PJ, Schlossmacher MG, Sad S. K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo. Cell Death Differ. 2016 23(1) :1628-1637  

Mollenhauer B et al. Biological confounders for the values of cerebrospinal fluid protein in Parkinson’s disease and related disorders. J Neurochem. 2016; 139 Suppl 1 :290-317 

Fava VM et al. A Missense LRRK2 Variant Is a Risk Factor for Excessive Inflammatory Responses in Leprosy. PLoS Negl Trop Dis. 2016; 10(2) :e0004412.
* This paper is from Dr. Erwin Schurr’s team as part of the CLINT Consortium    

Rocha JD et al. LRRK2 and Nod2 promote lysozyme sorting in Paneth cells. Nat Immunol. 2015; 16(9):898-900.  

Gray MT et al. Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects. Mov Disord. 2014; 29(8) :991-998  
 
Sardi SP et al. Mutant GBA1 expression and synucleinopathy risk: First insights from cellular and mouse models. Neurodeg Dis 2012 ;10(1-4):195-202  

Kitada T*, Tomlinson JJ* et al. Considerations regarding the etiology and treatment of recessive versus idiopathic Parkinson disease. Curr Treat Opt Neurol 2012;14:230-40 

Cullen V*, Lindfors M* et al. Cathepsin D expression affects the processing, aggregation and toxicity of a-synuclein in vivo. Mol Brain 2009;2:5(1-17)
* This paper was awarded the editor’s ‘Molecular Brain Award’ in 2012  

Tomlinson JJ* et al. Identifying targets in a-synuclein metabolism to treat Parkinson’s and related disorders. Protein Misfolding Diseases. Editors: M. Ramirez- Alvarado, J. Kelly and C. Dobson. Wiley & Son Inc. 2010;37:817-42

Klein C et al. Translational Research in Neurology and Neuroscience 2011: Movement Disorders. Arch Neurol 2011;68:709-16  

Mollenhauer B et al. Total CSF a-synuclein is lower in de novo Parkinson’s disease patients than in healthy controls. Neurosci Lett 2013; 532:44-8  

PubMed Listings

For more publications use this PubMed ID link.